An app through which users can analyze their urine samples from their smartphones is under FDA scanner.

However the FDA has sent a notice asking that as the app converted the user’s phone into an automated strip reader, why did not the company seek FDA’s approval before its release.
Biosense acknowledged that they have been contacted by the FDA and its co-founder, Myshkin Ingawale said that his company will be working close with the health regulatory body to ensure that they provide an accurate diagnostic tool. “We are in communication with the FDA as per their latest letter, and will be working closely with them over the coming months to ensure that we continue to deliver accurate, affordable and convenient diagnostics across the world”, he said.
Source-Medindia